Table 2.
Anti-poliovirus antibodies before and after the booster vaccination by group.
| sIPV-2bOPV-sIPV(n = 114) | 2sIPV-bOPV-bOPV(n = 54) | 2sIPV-bOPV-sIPV(n = 58) | 3sIPV-bOPV(n = 65) | 4sIPV(n = 61) | χ2/F | P value | |
|---|---|---|---|---|---|---|---|
| Anti-poliovirus serotype 1 antibody | |||||||
| Pre-booster | |||||||
| Seropositive | 114 (100%) | 53 (98.15%) | 58 (100%) | 65 (100%) | 61 (100%) | – | 0.153 |
| GMT | 1026.73 | 976.31 | 650.7 | 426.69 | 441.61 | 16.568 | <0.001 |
| Post-booster | |||||||
| Seropositive | 114 (100.00%) | 54 (100.00%) | 58 (100.00%) | 65 (100.00%) | 61 (100.00%) | – | – |
| Seroconversion | 100 (87.72%) | 25 (46.30%) | 55 (94.83%) | 64 (98.46%) | 60 (98.36%) | 92.850 | <0.001 |
| GMT | 12568.55 | 5337.42 | 11753.85 | 12825.75 | 11957.62 | 12.072 | <0.001 |
| Anti-poliovirus serotype 2 antibody | |||||||
| Pre-booster | |||||||
| Seropositive | 48 (42.11%) | 42 (77.78%) | 43 (74.14%) | 58 (89.23%) | 57 (93.44%) | 72.278 | <0.001 |
| GMT | 11.26 | 26.95 | 17.56 | 42.62 | 33.76 | – | <0.001 |
| Post-booster | |||||||
| Seropositive | 114 (100.00%) | 50 (92.59%) | 58 (100.00%) | 64 (98.46%) | 61 (100.00%) | – | 0.002 |
| Seroconversion | 105 (92.11%) | 16 (29.63%) | 58 (100.00%) | 40 (61.54%) | 61 (100.00%) | 137.299 | <0.001 |
| GMT | 1112.70 | 50.60 | 3604.50 | 247.84 | 5518.18 | – | <0.001 |
| Anti-poliovirus serotype 3 antibody | |||||||
| Pre-booster | |||||||
| Seropositive | 114 (100.00%) | 53 (98.15%) | 58 (100.00%) | 61 (93.85%) | 56 (91.80%) | – | 0.002 |
| GMT | 300.26 | 422.03 | 345.30 | 75.07 | 90.11 | – | <0.001 |
| Post-booster | |||||||
| Seropositive | 114 (100.00%) | 54 (100.00%) | 58 (100.00%) | 65 (100.00%) | 61 (100.00%) | – | |
| Seroconversionn | 112 (98.25%) | 31 (57.41%) | 56 (96.55%) | 58 (89.23%) | 59 (96.72%) | 76.655 | <0.001 |
| GMT | 10955.87 | 1860.73 | 9931.75 | 5962.40 | 8125.64 | – | <0.001 |
sIPV = Sabin inactivated poliovirus vaccine; bOPV = bivalent oral polio vaccine; GMT = geometric mean titre.